

Interview Summary	Application No.		Applicant(s)	
	09/281,717		BAXTER ET AL.	
	Examiner		Art Unit	
	Marjorie A. Moran		1631	

All participants (applicant, applicant's representative, PTO personnel):

(1) Marjorie A. Moran. (3) _____.

(2) Richard Bone. (4) _____.

Date of Interview: 15 October 2003.

Type: a) ☒ Telephonic b) ☐ Video Conference
c) ☐ Personal [copy given to: 1) ☐ applicant 2) ☐ applicant's representative]

Exhibit shown or demonstration conducted: d) ☐ Yes e) ☒ No.
If Yes, brief description: _____.

Claim(s) discussed: All pending.

Identification of prior art discussed: SCANLAN.


Agreement with respect to the claims f) ☐ was reached. g) ☒ was not reached. h) ☐ N/A.

Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: See Continuation Sheet.

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN ONE MONTH FROM THIS INTERVIEW DATE, OR THE MAILING DATE OF THIS INTERVIEW SUMMARY FORM, WHICHEVER IS LATER, TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.

Examiner Note: You must sign this form unless it is an Attachment to a signed Office action.


Examiner's signature, if required

Continuation of Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: The examiner clarified the restriction requirement and apologized for the confusion caused by the previous office actions. She stated that she considered the different, specific, receptors to be different compounds/products, and therefore considered a method of use of each product to be a distinct method from a method of use of any other product. The examiner stated that although the independent method is broad, she does not consider this situation to be one of genus/species, and gave further reasons for her opinion in this regard. The attorney and examiner discussed some possible amendments to overcome the new matter rejection; the examiner stated that any amendment would be subject to further search and review, and must be fully supported and enabled by the original disclosure. The examiner stated that if SCANLAN were commonly owned, the prior art rejections currently of record would be overcome; however, the rejections will be maintained until a proper statement to that effect is filed .